Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections San Francisco, CA March 9-12 2025 Back

Tweet

Bictegravir + Lenacapavir: Baseline and Week 48 Resistance Analyses in ARTISTRY-1 Phase 2       CROI 2025 SF March 9-12   Nicolas Margot, Nina Pennetzdorfer, Vidula Naik, Mauricio Montezuma, Peter Sklar, Christian Callebaut   Gilead Sciences, Inc., Foster City, CA, USA   "At Baseline, 43%, 19%, 11%, and 27% of participants were taking 2, 3, 4, or 5 pills or more/day, respectively."